On June 9, 2022 Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, reported that the company will participate in a number of investor and scientific conferences in June 2022 (Press release, Chemomab, JUN 9, 2022, View Source [SID1234615815]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
JMP Securities Life Sciences Conference:
Date: Thursday, June 16, 2022
Venue: Lotte Palace Hotel, New York, NY USA
Format: In-person live and webcast presentation; One-on-one meetings on June 16
Time: 11:00 a.m. ET
Link: View Source
Information: View Source
A replay of the webcast will be available at the Investor section of Chemomab’s website for at least 30 days.
The Extracellular Matrix Pharmacology Congress
Date: June 23-25, 2022
Venue: Tivoli Congress Center, Copenhagen, Denmark
Format: Poster presentation: CCL24 Inhibition by CM-101 Attenuates Extracellular Matrix and Fibrotic Biomarkers in Both Patients and Experimental Murine Models, Abstract ID:155
Time: Poster Session 1, June 23 from 13:00 – 14:15 CET
Presenter: Udi Gluschnaider, PhD, Chemomab Project Lead
Information: ECM Congress (ecm-congress.org)
A copy of the poster will be available at the R&D section of Chemomab’s website starting on June 23, 2022.
EASL: The International Liver Congress 2022
Date: June 22-26, 2022
Venue: ExCeL London, London, UK, and virtual
Format: Oral poster presentation: Combination of whole liver single cell RNA sequencing and spatial transcriptomics reveals specific cell sub-populations and pathways regulated by CCL24, Abstract Identifier: OS02
Presenter: Raanan Greenman, PhD, Chemomab Project Lead
Time: June 23, 2022, 16:45 CET
Session: Immune-mediated and cholestatic: Experimental and pathophysiology
Information: View Source
The presentation will be available at the R&D section of Chemomab’s website starting on June 24, 2022
In addition, Chemomab’s business development team members will be in San Diego, California June 13-16, 2022, participating in the BIO International Convention’s One-on-One Partnering event. Registered attendees can click here to log in and schedule a meeting with Chemomab.